Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD).
Porcari S, Viola A, Orlando A, Privitera AC, Ferracane C, Cappello M, Vitello A, Siringo S, Inserra G, Magnano A, Mocciaro F, Di Mitri R, Belluardo N, Fidanza O, Garufi S, Magrì G, Bertolami C, Carroccio A, Macaluso FS, Renna S, Ventimiglia M, Alibrandi A, Cottone M, Fries W; Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). Porcari S, et al. Among authors: garufi s. Drugs Aging. 2020 May;37(5):383-392. doi: 10.1007/s40266-020-00744-3. Drugs Aging. 2020. PMID: 32016824
A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis.
Renna S, Mocciaro F, Ventimiglia M, Orlando R, Macaluso FS, Cappello M, Fries W, Mendolaro M, Privitera AC, Ferracane C, Pisana V, Magnano A, Pluchino D, Inserra G, Scarpulla G, Garufi S, Carroccio A, Siringo S, Di Mitri R, Cottone M, Orlando A. Renna S, et al. Among authors: garufi s. Dig Liver Dis. 2018 Dec;50(12):1292-1298. doi: 10.1016/j.dld.2018.06.008. Epub 2018 Jun 22. Dig Liver Dis. 2018. PMID: 30007516
The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches.
Macaluso FS, Fries W, Viola A, Centritto A, Cappello M, Giuffrida E, Privitera AC, Piccillo G, Magnano A, Vinci E, Vassallo R, Trovatello A, Belluardo N, Giangreco E, Camilleri S, Garufi S, Bertolami C, Ventimiglia M, Renna S, Orlando R, Rizzuto G, Orlando A. Macaluso FS, et al. Among authors: garufi s. Inflamm Bowel Dis. 2021 Jan 19;27(2):182-189. doi: 10.1093/ibd/izaa036. Inflamm Bowel Dis. 2021. PMID: 32083291
A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease.
Macaluso FS, Ventimiglia M, Fries W, Viola A, Sitibondo A, Cappello M, Scrivo B, Busacca A, Privitera AC, Camilleri S, Garufi S, Di Mitri R, Mocciaro F, Belluardo N, Giangreco E, Bertolami C, Renna S, Orlando R, Rizzuto G, Cottone M, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Macaluso FS, et al. Among authors: garufi s. J Gastroenterol Hepatol. 2021 Jan;36(1):105-111. doi: 10.1111/jgh.15107. Epub 2020 Jun 8. J Gastroenterol Hepatol. 2021. PMID: 32428981
Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study.
Macaluso FS, Fries W, Renna S, Viola A, Muscianisi M, Cappello M, Guida L, Siringo S, Camilleri S, Garufi S, Privitera AC, Belluardo N, Giangreco E, Bertolami C, Vassallo R, Rizzuto G, Orlando R, Ventimiglia M, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Macaluso FS, et al. Among authors: garufi s. United European Gastroenterol J. 2020 Nov;8(9):1045-1055. doi: 10.1177/2050640620948802. Epub 2020 Aug 9. United European Gastroenterol J. 2020. PMID: 32772830 Free PMC article.
Effectiveness of Ustekinumab on Crohn's Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD).
Macaluso FS, Fries W, Viola A, Costantino G, Muscianisi M, Cappello M, Guida L, Giuffrida E, Magnano A, Pluchino D, Ferracane C, Magrì G, Di Mitri R, Mocciaro F, Privitera AC, Camilleri S, Garufi S, Renna S, Casà A, Scrivo B, Ventimiglia M, Orlando A. Macaluso FS, et al. Among authors: garufi s. Expert Opin Biol Ther. 2020 Nov;20(11):1381-1384. doi: 10.1080/14712598.2020.1830057. Epub 2020 Oct 9. Expert Opin Biol Ther. 2020. PMID: 32981373
Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseases.
Viola A, Muscianisi M, Macaluso FS, Ventimiglia M, Cappello M, Privitera AC, Magnano A, Pluchino D, Magrì G, Ferracane C, Mocciaro F, Garufi S, Giuffrida E, Costantino G, Fiocco G, Grova M, Guida L, Alibrandi A, Orlando A, Fries W; “Sicilian Network for Inflammatory Bowel Disease (SN‐IBD)”. Viola A, et al. Among authors: garufi s. JGH Open. 2021 Feb 2;5(3):364-370. doi: 10.1002/jgh3.12502. eCollection 2021 Mar. JGH Open. 2021. PMID: 33732883 Free PMC article.
SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501.
Macaluso FS, Cappello M, Busacca A, Fries W, Viola A, Costantino G, Magnano A, Vinci E, Ferracane C, Privitera AC, Piccillo G, Belluardo N, Giangreco E, Romano C, Citrano M, Graziano F, Garufi S, Bertolami C, Ventimiglia M, Scrivo B, Teresi G, Renna S, Rizzuto G, Casà A, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Macaluso FS, et al. Among authors: garufi s. J Gastroenterol Hepatol. 2021 Nov;36(11):3041-3049. doi: 10.1111/jgh.15590. Epub 2021 Jul 3. J Gastroenterol Hepatol. 2021. PMID: 34152636
Letter: SPOSIB SB2-a Sicilian prospective observational study of IBD patients treated with infliximab biosimilar SB2.
Macaluso FS, Cappello M, Giuffrida E, Fries W, Centritto A, Privitera AC, Inserra G, Vassallo R, Magnano A, Vinci E, Garufi S, Ventimiglia M, Renna S, Orlando R, Rizzuto G, Cottone M, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Macaluso FS, et al. Among authors: garufi s. Aliment Pharmacol Ther. 2019 Jan;49(2):234-236. doi: 10.1111/apt.15071. Aliment Pharmacol Ther. 2019. PMID: 30589969 No abstract available.
A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis.
Macaluso FS, Ventimiglia M, Fries W, Viola A, Cappello M, Scrivo B, Magnano A, Pluchino D, Camilleri S, Garufi S, Mitri RD, Mocciaro F, Magrì G, Ferracane C, Citrano M, Graziano F, Bertolami C, Renna S, Orlando R, Rizzuto G, Cottone M, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD).. Macaluso FS, et al. Among authors: garufi s. Dig Liver Dis. 2020 Dec;52(12):1461-1466. doi: 10.1016/j.dld.2020.06.014. Epub 2020 Jun 26. Dig Liver Dis. 2020. PMID: 32601033
18 results